Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Kate Cwynarski, Gloria Iacoboni, Eleni Tholouli, Tobias F. Menne, David A. Irvine, Nivetha Balasubramaniam, Leigh Wood, Justin Shang, Yiyun Zhang, Silvia Basilico, Birgit Huber, Mary Vinson, Koki Lilova, Wolfram Brugger, Martin Pule

Blood (2022) 140 (Supplement 1): 10316–10317.

https://doi.org/10.1182/blood-2022-165971

Published: 2022

Journal Articles

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Blood (2022) 140 (Supplement 1): 1761–1764.

https://doi.org/10.1182/blood-2022-166543

Published: 2022

Journal Articles

Improvement in Lymphoma CAR-T Outcomes over Time in the UK - CAR-T Learning Curve or Better Bridging?

Stephen Boyle, Robin Sanderson, Maeve A. O'Reilly, Tobias F. Menne, Jane Norman, Adrian Bloor, Sanne Lugthart, Sridhar Chaganti, Carlos Gonzalez-Arias, Ceri Jones, Anne-Louise Latif, Reuben Benjamin, Piers Patten, Deborah Yallop, Victoria Potter, Claire Roddie, Andrea Kuhnl

Blood (2022) 140 (Supplement 1): 4649–4651.

https://doi.org/10.1182/blood-2022-159217

Published: 2022

Journal Articles

Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp

Blood (2021) 138 (Supplement 1): 877.

https://doi.org/10.1182/blood-2021-146242

Published: 2021

Journal Articles

CAR-T Toxicity Management and Steroid Use in High-Grade B-Cell Lymphoma: Impact on Real-World Survival Outcomes in the UK

Blood (2021) 138 (Supplement 1): 531.

https://doi.org/10.1182/blood-2021-149501

Published: 2021

Journal Articles

Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial

Blood (2021) 138 (Supplement 1): 2492.

https://doi.org/10.1182/blood-2021-146494

Published: 2021

Journal Articles

First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006)

Clare J Rowntree, Amy A Kirkwood, Laura Clifton-Hadley, Nadine Farah, Marc R. Mansour, Jiaull Hussain, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Pip Patrick, Bela Wrench, Adele K. Fielding

Blood (2021) 138 (Supplement 1): 366.

https://doi.org/10.1182/blood-2021-152355

Published: 2021

Journal Articles

Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-135999

Published: 2020

Journal Articles

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Kami J. Maddocks, MD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, Anna Marina Liberati, MD, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MDPhD, Gianluca Gaidano, Pau Abrisqueta, MD PhD, Marc André, MD, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles Salles, MDPhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-140314

Published: 2020

Journal Articles

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, MD, Kami J. Maddocks, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, MD PhD, Anna Marina Liberati, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MD PhD, Gianluca Gaidano, MD PhD, Pau Abrisqueta, MD PhD, Marc André, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles A. Salles, MD PhD

Blood (2019) 134 (Supplement_1): 1582.

https://doi.org/10.1182/blood-2019-122573

Published: 2019

Journal Articles

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Blood (2019) 134 (Supplement_1): 1564.

https://doi.org/10.1182/blood-2019-125256

Published: 2019

Journal Articles

Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14

Anthony V. Moorman, Ellie Butler, Emilio Barretta, Amy A. Kirkwood, MSc, Claire Schwab, PhD, Thomas Creasey, MBBS, Daniel A. Leongamornlert, PhD, Elli Papaemmanuil, PhD, Pip Patrick, PhDMSc,MA, Laura Clifton-Hadley, PhDBSc, Bela Wrench, MBBS, MD MRCP, FRCPath, Tobias F Menne, MD PhD FRCPath, Andrew K McMillan, FRCP, Christine J. Harrison, PhD FRCPath, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David I Marks, MBBS, PhD FRCPath, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 288.

https://doi.org/10.1182/blood-2019-123642

Published: 2019

Journal Articles

Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials

Thomas Creasey, MBBS, Emilio Barretta, Amy A. Kirkwood, MSc, Claire Schwab, PhD, Pip Patrick, PhDMSc,MA, Laura Clifton-Hadley, PhDBSc, Bela Wrench, MBBS, MD MRCP, FRCPath, Tobias F Menne, MD PhD FRCPath, Andrew K McMillan, FRCP, Nicholas J. Morley, John A Snowden, BSc (Hons), MBChB, MD FRCP, FRCPath, Christine J. Harrison, PhD FRCPath, Daniel A. Leongamornlert, PhD, Elli Papaemmanuil, PhD, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David I Marks, MBBS, PhD FRCPath, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Anthony V. Moorman

Blood (2019) 134 (Supplement_1): 2746.

https://doi.org/10.1182/blood-2019-124395

Published: 2019

Journal Articles

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Amer M. Zeidan, MBBS, MHS, Michael W. Schuster, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Magalie Joris, MD, Tobias F Menne, MD PhD FRCPath, Paresh Vyas, MD PhD, Weidong Wendy Ma, Ashleigh O'Connell, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 3916.

https://doi.org/10.1182/blood-2019-124034

Published: 2019

Journal Articles

Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Sonja Zweegman, MD PhD, Jim Cavet, FRCPath, Kwee Yong, Lydia Lee, Jim Faulkner, Ekaterini Kotsopoulou, Muhammad Al-Hajj, Simon Thomas, PhD, Shaun P Cordoba, PhD, Martin Pule, MD, Virginie Cerec, PhD, Vijay G R Peddareddigari, Nushmia Z Khokhar, MD, Tobias F Menne, MD PhD FRCPath

Blood (2019) 134 (Supplement_1): 3112.

https://doi.org/10.1182/blood-2019-126689

Published: 2019

Journal Articles

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

David I Marks, MBBS, PhD FRCPath, Amy A. Kirkwood, MSc, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Melanie Aguiar, BSc, Katharine E Bailey, MBBS, FRCPath, MA, MRCP, Brendan Beaton, MD, Laura Clifton-Hadley, PhDBSc, Emma Lawrie, BSc, SooWah Lee, MSc, Andrew K McMillan, FRCP, Anthony V. Moorman, PhD, Rachel J. Mitchell, MSc, Pip Patrick, PhDMSc,MA, Tobias F Menne, MD PhD FRCPath, Paul Smith, Bela Wrench, MBBS, MD MRCP, FRCPath, Krisztina Zuborne Alapi, MSc, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 739.

https://doi.org/10.1182/blood-2019-123374

Published: 2019

Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Blood (2019) 134 (Supplement_1): 767.

https://doi.org/10.1182/blood-2019-124177

Published: 2019

Journal Articles

Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

Sarah E Fordham, PhD, Helen J Blair, PhD, Claire J Elstob, PhD, Deepali Pal, PhD, Nicola Curtin, PhD, Paul Milne, PhD, Matthew Collin, MD PhD, Graham H Jackson, MD MBBS, Helen J Marr, MD PhD, Olaf Heidenreich, PhD, Ruth Plummer, John Pollard, PhD, Tobias F. Menne, MD PhD FRCPath, Gail L Jones, MD BMBS, James M Allan, DPhil

Blood (2016) 128 (22): 4031.

https://doi.org/10.1182/blood.V128.22.4031.4031

Published: 2016

Journal Articles

Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Dina Okasha, Amy A Kirkwood, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Emma Lawrie, Andrew McMillan, PhD, Tobias F. Menne, MD PhD FRCPath, Nick Morley, Clare Rowntree, Deborah Susan Richardson, MDFRCPath,FRCP,MA,MBBChir, Paul Smith, Adele K. Fielding, MB BS, PhD, David Marks, MD PhD

Blood (2015) 126 (23): 733.

https://doi.org/10.1182/blood.V126.23.733.733

Published: 2015

Journal Articles

Altered Hematopoiesis in Trisomy 21 As Revealed Through In Vitro Differentiation of Isogenic Human Pluripotent Cells

Glenn A. MacLean, Ph.D, Tobias F. Menne, MD, PhD, MRCP, FRCPath, In-Hyun Park, PhD, George Q. Daley, MD, PhD, Stuart H. Orkin, MD

Blood (2011) 118 (21): 921.

https://doi.org/10.1182/blood.V118.21.921.921

Published: 2011

NARROW

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Improvement in Lymphoma CAR-T Outcomes over Time in the UK - CAR-T Learning Curve or Better Bridging?

Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp

CAR-T Toxicity Management and Steroid Use in High-Grade B-Cell Lymphoma: Impact on Real-World Survival Outcomes in the UK

Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial

First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006)

Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14

Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Altered Hematopoiesis in Trisomy 21 As Revealed Through In Vitro Differentiation of Isogenic Human Pluripotent Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only